Century Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Century Therapeutics, Inc. (IPSC) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$13.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$11.25M.
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$6.57M.
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$512.00K, a 119.95% decline year-over-year.
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $2.57M, a 96.31% decline year-over-year.
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $3.80M, a 68.11% decline from fiscal 2024.
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $11.91M.
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$36.94M, a 231.55% decline from fiscal 2022.
- Century Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $28.08M, a 7.73% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$13.01M 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | -$11.25M 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | $3.80M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | -$2.54M 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | -$1.63M 10-Q · filed 2026-08-12 | |||
| 2025-03-31 | -$6.57M 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | $11.91M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $6.13M 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | -$5.01M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$512.00K 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$36.94M 10-K · filed 2025-03-19 | |||
| 2023-09-30 | -$28.96M 10-Q · filed 2024-11-05 | |||
| 2023-06-30 | -$19.83M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $2.57M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $28.08M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $55.17M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $56.60M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $69.59M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $30.43M 10-K · filed 2023-03-16 | |||
| 2021-09-30 | $75.28M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |